Treatment of Advanced-Stage Rectal Cancer

Introduction to Treatment Approach

• The American Society of Clinical Oncology recommends total neoadjuvant therapy (TNT) consisting of long-course chemoradiotherapy followed by consolidation chemotherapy for patients with advanced-stage rectal cancer, followed by total mesorectal excision surgery 6-8 weeks after completion of neoadjuvant therapy 1, 2

Risk Stratification and Treatment Selection

• High-risk features requiring TNT include T4 tumors, low rectal tumors, threatened mesorectal fascia, extramural vascular invasion, tumor deposits, cN2 disease, and enlarged lateral lymph nodes, as identified by high-resolution pelvic MRI with dedicated rectal sequences 1, 2

Optimal TNT Regimen

• The preferred TNT sequence is long-course chemoradiotherapy (50.4 Gy with concurrent fluoropyrimidine) followed by consolidation chemotherapy (3 cycles of FOLFOX or XELOX), with surgery 6-8 weeks after completion of neoadjuvant therapy 1, 2, 3
• Long-course chemoradiotherapy is strongly preferred over short-course radiotherapy due to superior local control, with a 5-year locoregional failure rate of 6% versus 10% (P=0.027) 2

Surgical Management

• Total mesorectal excision (TME) remains the surgical standard and should be performed 6-8 weeks after completion of chemoradiotherapy to allow maximal tumor downstaging, achieving local recurrence rates below 10% 1, 3

Special Populations

• For tumors that are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), immunotherapy is the recommended treatment rather than standard chemoradiotherapy 1, 2

Postoperative Management

• Patients who undergo surgery after TNT should receive postoperative adjuvant chemotherapy to complete a total treatment duration of 6 months, with fluoropyrimidine monotherapy considered for patients with pathological stage ≤ypII after TNT 2

Management of Unresectable Disease

• For patients with fixed tumors or local recurrence, preoperative radiotherapy with or without concurrent chemotherapy should be administered, with attempts at radical surgery 4-8 weeks after radiotherapy 3
• First-line palliative chemotherapy consists of 5-FU/leucovorin in combination with oxaliplatin (FOLFOX), with a hazard ratio for overall survival of 0.65 (95% CI 0.53-0.80, p<0.0001) compared to irinotecan-based regimens 3

Critical Pitfalls to Avoid

• Do not use short-course radiotherapy for patients with high-risk features requiring optimal local control, as this approach increases locoregional recurrence 2
• Ensure MSI/MMR testing is completed before initiating treatment, as MSI-H/dMMR tumors require immunotherapy rather than standard chemoradiotherapy 1, 2